{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-027244","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.953381+00:00","generated_at":"2026-05-16T13:32:50.512599+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MAIA dosed first patient in THIO-104 Phase 3 trial of ateganosine for third-line NSCLC","bullets":["First patient dosed in THIO-104 Phase 3 pivotal trial evaluating ateganosine + CPI vs chemo in third-line NSCLC.","Trial targets up to 300 patients with primary endpoint of overall survival; screening underway in Taiwan, Turkey, EMA countries, Georgia.","CEO Vitoc and board purchased ~182,445 shares on open market Nov 21–28, 2025; insiders now hold 12.95% of company.","Phase 2 data showed median OS 17.8 months vs ~6 months for chemo; FDA granted Fast Track designation for ateganosine."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-027244","json":"https://secwatch.observer/filing/0001493152-25-027244.json","markdown":"https://secwatch.observer/filing/0001493152-25-027244.md","text":"https://secwatch.observer/filing/0001493152-25-027244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225027244/0001493152-25-027244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225027244/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:32:50.512599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}